| 000 | 01871 a2200589 4500 | ||
|---|---|---|---|
| 005 | 20250516143348.0 | ||
| 264 | 0 | _c20131211 | |
| 008 | 201312s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdt117 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStacchiotti, S | |
| 245 | 0 | 0 |
_aPhase II study on lapatinib in advanced EGFR-positive chordoma. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cJul 2013 |
||
| 300 |
_a1931-1936 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aChordoma _xdrug therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aErbB Receptors _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLapatinib |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 |
_aSacrum _xpathology |
| 650 | 0 | 4 |
_aSkull Base _xpathology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTamborini, E | |
| 700 | 1 | _aLo Vullo, S | |
| 700 | 1 | _aBozzi, F | |
| 700 | 1 | _aMessina, A | |
| 700 | 1 | _aMorosi, C | |
| 700 | 1 | _aCasale, A | |
| 700 | 1 | _aCrippa, F | |
| 700 | 1 | _aConca, E | |
| 700 | 1 | _aNegri, T | |
| 700 | 1 | _aPalassini, E | |
| 700 | 1 | _aMarrari, A | |
| 700 | 1 | _aPalmerini, E | |
| 700 | 1 | _aMariani, L | |
| 700 | 1 | _aGronchi, A | |
| 700 | 1 | _aPilotti, S | |
| 700 | 1 | _aCasali, P G | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 24 _gno. 7 _gp. 1931-1936 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdt117 _zAvailable from publisher's website |
| 999 |
_c22643537 _d22643537 |
||